A Review of the Latest Biomarkers for Cancer Diagnosis and Monitoring

Cancer is one of the main public health problems linked to increased mortality and intergroup migration. There are some known drawbacks to the therapeutic techniques used today. For example, a significant percentage of patients do not improve following chemotherapy and instead suffer a disease-related recurrence. A multitude of internal and external variables have a substantial impact on how cancer is managed. [1] An estimated 530,000 Americans lost their lives to cancer in 1993, making up 23% of all preventable fatalities. (3). According to the National Cancer Institute's 1993 SEER report, fatalities from colon, stomach, breast, and prostate cancers account for 55% of all cancer-related deaths. [2] Breast cancer is the leading cause of cancer-related deaths among women in the United States and the second most common kind of cancer in this demographic. The term "breast" The term "cancer" describes malignancies that start in the breast tissue, usually in the milk-producing lobules or milk ducts. Breast cancer is the second most frequent non-skin cancer globally (after lung cancer) and the sixth leading cause of cancer death, accounting for 10.4% of all cancer cases in women. In 2004, breast cancer claimed the lives of 519,000 people worldwide, accounting for 7% of all cancer deaths and more than 1% of all fatalities. Although males are typically diagnosed with breast cancer later than women, their prognoses are usually worse. [3] Lung cancer, the second most frequent disease in both men and women, accounts for 30% of all cancer-related fatalities in the US annually. Women die from lung cancer about twice as frequently as they do from breast cancer, and men die from lung cancer more than three times as frequently as they [4] Prostate cancer accounts for 33% of newly diagnosed male cancers in the United States. It is projected that 220,900 men will receive a prostate cancer diagnosis in 2003. The American Cancer Society estimates that the illness will claim the lives of 28,900 men. [5]

Biomarker for cancer

A characteristic that can be used to predict a patient's prognosis or likelihood of developing cancer is called a cancer biomarker. Evidence from genetic, cellular, physiological, or imaging studies may support the existence of these characteristics. The present research focuses on molecular and cellular cancer biomarkers. These biomolecules can be found in body fluids or tissues and are produced by or found in cancer cells as well as healthy cells in response to malignancy. One way to identify cancer indications is to do a DNA, RNA, or protein profile on tumours or body fluids. [6] Finding these biomarkers could help us better understand the processes underlying immunotherapy's therapeutic benefits and aid in the creation of novel combination medications. It would also assist those who are unlikely to benefit from the medication in avoiding its side effects and associated costs. [7] Two studies looked at biomarkers in sALS patients using plasma, the portion of blood that includes clotting factors. Following microarray analysis, Takahashi et al. used RT-qPCR. [8].

Cancer Biomarkers using Radiogenetics and Radiogenomics:

Molecular Biomarkers:

As sensitive "early warning" tools for gauging biological consequences in environmental quality assessment, the use of biological markers or biomarkers assessed at the molecular and cellular level is crucial. Radiogenomics is based on the premise that it is possible to investigate the relationship between imaging, genomics, and clinical knowledge only by data analysis, without any qualitative interpretation; in other words, by letting the facts speak for themselves [9]. Radiogenetics biomarkers are employed as costly integration biomarkers in contrast to Radiogenomics. Historically, the diagnosis and classification of cancer have been based on the histological examination of bioptic tissues. The incapacity to distinguish between clinically significant cancer subtypes, invasive tissue collection, and inter- and intra-observer variability are some of the disadvantages of this approach [10]. Although the core concepts of Radiogenomics are fairly simple, there is much disagreement about how broadly they should be defined. [11] Ambiguity may be explained in two major ways. The prefix radio, which may be used to refer to radiation, is the source of the word "Radiogenomics," which is intended to mean "radiation genomics." Finding genes with single nucleotide polymorphisms (SNPs) as possible biomarkers of radiation-induced side effects and creating an assay that can forecast which cancer patients will be toxically affected by radiation therapy treatment should be the main objectives. The suffix "omics," which implies that every biological and imaging sample will yield complex, high-dimensional, mineable data, provides the second justification. [12]

Cellular biomarker

Clinical and laboratory examinations can make use of cellular biomarkers, which are biological and quantifiable signs. Cellular biomarkers are frequently examined and assessed in soft tissue, bodily fluids, or blood to determine prognosis or likelihood of response to a particular treatment. Cells may be isolated, sorted, quantified, and characterised using these biomarkers based on their morphological and physiological characteristics [13, 14]. Cellular phenotype, or variations in cell shape and function, can be caused by changes in gene and protein expression. The range of pathways involved in the production of that specific trait is reflected in these phenotypic aspects. Thus, physiological reactions, including oxidative stress levels, cell death (apoptosis), DNA damage response (including DNA repair), and others, can be utilised as biological biomarkers for cancer. Notably, a high-throughput phenotypic test that analyses the cellular biomarker could be simpler to utilise in a clinical environment than gene analysis assays.

Cancer Biomarker Types

1. Biomarkers of Genetics:

Gene alterations and mutations: Gene alterations and mutations are significant cancer biomarkers that can provide critical details about the underlying genetic changes causing cancer to originate and spread. These are a few instances of cancer biomarkers based on gene alterations and mutations. In individuals with melanoma, the BRAF V600E mutation promotes cell proliferation, which helps with the selection of targeted treatment [15]. Non-small-cell lung cancer (NSCLC) patients with EGFR mutations (such as exon 19 deletions and L858R point mutations) are more susceptible to EGFR inhibitors [16]. HER2 amplification/ overexpression indicates aggressive behaviour in breast/ gastric cancer, and is generally treated with anti-HER2 antibodies [17]. IDH mutations affect cellular metabolism and serve as diagnostic and prognostic markers in glioma patients [18]

Profiles of Gene Expression: In order to give information on tumour activity, prognosis, and treatment response, gene-expression-profile-based cancer biomarkers examine the V-patterns of gene expression in cancer cells. Here are a few instances of cancer biomarkers based on gene expression profiles. When breast cancer is oncotype DX: A genetic test called Oncotype DX evaluates the expression of a panel of around 16 genes linked to breast cancer. It offers a recurrence score (RS) that helps guide treatment choices and forecasts the chance of disease recurrence, especially in early-stage hormone receptor-positive breast cancer.[19]

DNA as a Cancer Biomarker: Cancer, especially neoplastic with metastatic spread, has been found to be associated with elevated blood DNA concentrations. DNA biomarkers include oncogene changes, mutations in mismatch-repair genes, and mutations in tumour suppressor genes 2024, 24, 37 9 of 55. Polymorphisms in the KRAS oncogene signify systemic progression, while mutations in the p53 tumour suppressor gene are detected in more than 50% of sporadic malignancies [20–22]. The risk of developing many of the same malignancies is increased by a TP53 mutation that is inherited (Li-Fraumeni syndrome). Single-nucleotide polymorphisms can be found in some genes, such as XRCC1, p53, and ATM (lung, head, and neck cancers), PGS2 (lung cancer), and RAD1, CYP1A1, and BRCA1/2 (breast cancer). Mutations in DNA nucleotides in tumour promoters like APC, RAS, and tumour suppressor genes have been linked to diagnosis. Potential sources of DNA include cell membranes, sputum, serum, saliva, cerebrospinal fluid (CSF), bronchial tears, tumour cells circulating in the bone marrow, and blood [23–25].

2. Biomarkers for proteins

Proteins as Biomarkers for Cancer: The proteome is a complex system composed of several proteins that interact with one another through posttranslational changes and dynamic intermolecular interactions. Proteomic indicators are important for carcinogenesis and progression because they alter molecular processes and pathways in both normal and malignant cells [26,27].

Figure 1. Using body fluids, potential protein biomarkers for pancreatic cancer are identified.
Bile, blood, pancreatic juice, urine, and pancreatic cyst fluid are among the bodily fluids that include proteins produced by cancer.

Table 1. Cancer types and FDA-approved immunotherapies.

Antigens of Carbohydrates as Biomarkers for Cancer

The development of antibodies that target extracts or cell lines produced from malignancies has led to the identification of carbohydrate antigen (CA) biomarkers as cancer indicators. High molecular weight glycoproteins are CA indicators. CA19-9 is the most often used serum tumour biomarker for identifying digestive organ cancers. CA-125 is a validated diagnostic for ovarian cancer recurrence detection and medication response assessment [34].

4. Galectins as Biomarkers for Cancer

All species contain galectins, a class of beta-galactoside-binding lectins. Abnormal tumour-associated glutelectin expression is connected to the origin, development, and pathological aggressiveness of malignancies. Galectin-3 is more of a malignancy function-related biomarker that may be used in combination with specific other metabolic biomarkers than a carcinoma diagnosis biomarker. It increases angiogenesis and tumour development when released into the tumorstroma [35].

Classification Of Biomarker:

Figure 2. Classification of Biomarkers

 5.  Procedures for looking for novel biomarkers:

Even though there has been a lot of progress, the area of cancer research urgently needs to find and create new potent biomarkers. The discovery, assay development, analytical validation, clinical validation, clinical usefulness, and deployment are all steps in the process of creating

Figure 3. Cancer biomarker clinical application

6. Tissue-independent biomarkers

Tissue-agnostic biomarkers for cancer are a specific type of biomarker that provides information on the role or activity of certain molecules in tumour tissue. Unlike traditional biomarkers, which are centred on the detection of specific substances in blood or other physiological fluids, tissue agonistic biomarkers focus on the molecular interactions and signalling cascades occurring inside the tumour microenvironment. For example, the presence or activation of certain receptor tyrosine kinases, such as EGFR or HER2 (human epidermal growth factor receptor 2), in tumour tissue may indicate the need for a treatment approach targeting these receptors. [40–42]

Traditional Methods of Cancer Diagnosis

The greatest opportunity for a better prognosis is to diagnose cancer in its earliest stages. According to studies, preliminary detection of cancer through screening tests can save lives. Imaging studies, biopsies, laboratory testing, and physical examinations are some of the methods used to identify cancer. The laboratory tests involve searching for biomarkers in blood or other biological samples. A neoplasm may be detected if particular substances are present in the body in high or low concentrations. During the physical examination, the doctor may search for abnormalities that could indicate cancer, such as tumours, enlarged organs, or changes in skin tone. A biopsy is a kind of cancer diagnosis procedure in which a sample of cells is taken for examination in a lab. A sample can be taken using a variety of techniques, such as needle insertion and endoscopy. Another method of inquiry that allows the doctor to examine the inside organs is non-invasive imaging examinations. Imaging techniques used for diagnosing cancer include computed tomography (CT), positron emission tomography (PET), bone scans, ultrasound, X-rays, and magnetic resonance imaging (MRI). Imaging biomarkers, which are used in various kinds of diagnostic imaging, are crucial for both routinely managing cancer patients and clinical staging for the disease (TNM staging).

Table 2 Lists the imaging biomarkers that are clinically useful, along with their function.